Dr Rashmi Murthy speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the recent results from the HER2CLIMB study, which investigated the use of tucatinib in combination with capecitabine and trastuzumab versus placebo, in patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases.
She highlights that there is no single regimen that is considered as the standard of care, and there are very limited treatment options for patients with brain metastases.
Dr Murthy outlines the trial design and results from this study, which found that the combination of tucatinib, capecitabine and trastuzumab reduced the risk of death by a third.
She also discusses the management of patients with brain metastases and their representation in clinical trials.
Read more about the study here.